Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study

Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC) therapy, which is one of those methods. The aim of our study is to evaluate the effect of MSC treatment applied together with standard treatments on survival. Materials and Methods: This retrospective case-control study evaluates the survival effect of MSC treatment administered to patients treated in intensive care after the development of ARDS due to COVID-19 between March 2020 and March 2021. The age, gender, comorbid disease status, APACHE II score, and overall and comorbidity-based survival rates were compared between patients who received standard medical treatment (SMT) and patients who received MSC treatment together with SMT. Results: There were 62 patients in the group receiving only SMT and 81 patients in the group receiving SMT and MSC. No difference was observed between the groups in terms of age, gender, presence of comorbid diseases, or APACHE II scores. There were also no differences according to Kaplan-Maier analysis for the survival statuses of the groups. There was no serious adverse effect due to MSC treatment among these patients. Conclusion: Our study presents the largest case series in the literature, and it was observed that MSC treatment may not significantly affect overall survival or comorbid disease-based survival, in contrast to many other studies in the literature.

Anahtar Kelime:

Yoğun Bakım Ünitesindeki COVID-19 Hastalarında Mezenkimal Kök Hücre Tedavisinin Etkinliği

Öz:

Amaç: Akut solunum sıkıntısı sendromuna (ARDS) neden olan koronavirüs hastalığı 2019 (COVID-19) tedavisinde birçok yöntem kullanılmakta olup, literatürde mezenkimal kök hücre (MSC) tedavisinin sonuçları ile ilgili çelişkili yayınlar bulunmaktadır. Çalışmamızın amacı standart tedavilerle birlikte uygulanan MSC tedavisinin sağkalım üzerine etkisini değerlendirmektir. Gereç ve Yöntemler: Bu retrospektif olgu kontrol çalışması, Mart 2020 ile Mart 2021 arasında COVID-19’a bağlı ARDS gelişmesi sonrası yoğun bakımda tedavi edilen hastalara uygulanan MSC tedavisinin sağkalım etkisini değerlendirmektedir. Çalışmada, standart medikal tedavi (SMT) alan hastalar ile SMT ile birlikte MSC tedavisi alan hastalar arasında yaş, cinsiyet, komorbid hastalık durumu, APACHE II skoru, genel ve komorbiditeye dayalı sağkalım oranları karşılaştırıldı. Bulgular: Sadece SMT kullanan grupta 62 hasta, SMT ve MSC kullanan grupta 81 hasta vardı. Gruplar arasında yaş, cinsiyet, eşlik eden hastalık varlığı, Apache II skorları açısından fark gözlenmedi. Ayrıca grupların hayatta kalma durumları için Kaplan-Maier analizine göre herhangi bir farklılık yoktu. Hastalar arasında MSC tedavisine bağlı ciddi bir yan etki görülmedi. Sonuç: Çalışmamız literatürdeki en geniş olgu serisine sahip olup, literatürdeki birçok çalışmadan farklı olarak MSC tedavisinin hem genel sağkalıma hem de komorbid hastalık temelli sağkalıma anlamlı bir etkisi olmadığı görülmüştür.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-422.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18.844-847.
4. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052-2059.
5. Friedenstein AJ, Chailakhjan RK, Lalykina KS, The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Prolif 1970;3:393-403.
6. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991;9:641-650.
7. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008;2:313-319.
8. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-147.
9. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 1999;96:10711-10716.
10. Sato Y, Araki H, Kato J, Nakamura K, Kawano Y, Kobune M, Sato T, Miyanishi K, Takayama T, Takahashi M, Takimoto R, Iyama S, Matsunaga T, Ohtani S, Matsuura A, Hamada H, Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005;106:756-763.
11. Meirelles LDS, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 2006;119:2204-2213.
12. Marquez-Curtis LA, Janowska-Wieczorek A, McGann LE, Elliott JA. Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects. Cryobiology 2015;71:181-197.
13. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 2018;22:824-833.
14. Chan MC, Kuok DI, Leung CY, Hui KP, Valkenburg SA, Lau EH, Nicholls JM, Fang X, Guan Y, Lee JW, Chan RW, Webster RG, Matthay MA, Peiris JS. Human mesenchymal stromal cells reduce influenza A H5N1-associated acute lung injury in vitro and in vivo. Proc Natl Acad Sci U S A 2016;113:3621-3626.
15. Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L, Dai X, Xiang C, Li L. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: a hint for COVID-19 treatment. Engineering (Beijing) 2020;6:1153-1161.
16. Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK, Donahoe MP, McVerry BJ, Ortiz LA, Exline M, Christman JW, Abbott J, Delucchi KL, Caballero L, McMillan M, McKenna DH, Liu KD. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 2019;7:154-162.
17. Simonson OE, Mougiakakos D, Heldring N, Bassi G, Johansson HJ, Dalén M, Jitschin R, Rodin S, Corbascio M, El Andaloussi S, Wiklander OP, Nordin JZ, Skog J, Romain C, Koestler T, Hellgren-Johansson L, Schiller P, Joachimsson PO, Hägglund H, Mattsson M, Lehtiö J, Faridani OR, Sandberg R, Korsgren O, Krampera M, Weiss DJ, Grinnemo KH, Le Blanc K. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med 2015;4:1199-1213.
18. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee JW, Rogers AJ, Levitt J, Wiener-Kronish J, Bajwa EK, Leavitt A, McKenna D, Thompson BT, Matthay MA. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3:24-32.
19. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B, Xu J. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014;15:39.
20. Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, Yang T, Shi L, Fu J, Jiang T, Huang L, Zhao P, Yuan X, Fan X, Zhang JY, Song J, Zhang D, Jiao Y, Liu L, Zhou C, Maeurer M, Zumla A, Shi M, Wang FS. Human umbilical cord- derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther 2020;5:172.
21. Tsang HF, Chan LWC, Cho WCS, Yu ACS, Yim AKY, Chan AKC, Ng LPW, Wong YKE, Pei XM, Li MJW, Wong SC. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther 2021;19:877-888.
22. Rezoagli E, Murphy EJ, Laffey J, O’Toole D. The safety and efficiency of addressing ARDS using stem cell therapies in clinical trials. In: Burgess J, Heijink I (eds). Stem Cell-Based Therapy for Lung Disease. Cham, Springer Nature, 2019.
23. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67:533-539.
24. Li Y, Xu J, Shi W, Chen C, Shao Y, Zhu L, Lu W, Han X. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther 2016;7:1-11.
25. Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, Peiris JSM, Chan MCW. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1) virus-associated acute lung injury. J Infect Dis 2019;219:186-196.
26. Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, Hossieni H, Keshel SH, Naderpour Z, Hajizadeh-Saffar E, Shajareh E, Jamaati H, Soufi-Zomorrod M, Khavandgar N, Alemi H, Karimi A, Pak N, Rouzbahani NH, Nouri M, Sorouri M, Kashani L, Madani H, Aghdami N, Vasei M, Baharvand H. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther 2021;12:91.
27. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, Fan J, Wang W, Deng L, Shi H, Li H, Hu Z, Zhang F, Gao J, Liu H, Li X, Zhao Y, Yin K, He X, Gao Z, Wang Y, Yang B, Jin R, Stambler I, Lim LW, Su H, Moskalev A, Cano A, Chakrabarti S, Min KJ, Ellison-Hughes G, Caruso C, Jin K, Zhao RC. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020;11:216-228.
28. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician 2020;23:E71-83.
29. Weiss ARR, Dahlke MH. Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 2019;10:1191.
30. Walter J, Ware LB, Matthay MA. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir Med 2014; 2:1016-1026.
31. Meng SS, Guo FM, Zhang XW, Chang W, Peng F, Qiu HB, Yang Y. mTOR/ STAT-3 pathway mediates mesenchymal stem cell-secreted hepatocyte growth factor protective effects against lipopolysaccharide-induced vascular endothelial barrier dysfunction and apoptosis. J Cell Biochem 2019;120:3637-3650.
32. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009;106:16357-16362.
33. Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells 2019;8:784.
34. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z, Yang M, Xiao M, Nie P, Gao Y, Qian C, Hu M. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore) 2020;99:e21429.
35. Abu-El-Rub E, Khasawneh RR, Almahasneh F, Altaany Z, Bataineh N, Zegallai H, Sekaran S. Mesenchymal stem cells and COVID-19: What they do and what they can do. World J Stem Cells 2021;13:1318-1337.
36. Sánchez-Guijo F, García-Arranz M, López-Parra M, Monedero P, Mata- Martínez C, Santos A, Sagredo V, Álvarez-Avello JM, Guerrero JE, Pérez- Calvo C, Sánchez-Hernández MV, Del-Pozo JL, Andreu EJ, Fernández-Santos ME, Soria-Juan B, Hernández-Blasco LM, Andreu E, Sempere JM, Zapata AG, Moraleda JM, Soria B, Fernández-Avilés F, García-Olmo D, Prósper F. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EclinicalMedicine 2020;25:100454.
37. Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC, Hirani K, Bell CA, Kusack H, Rafkin L, Baidal D, Pastewski A, Gawri K, Leñero C, Mantero AMA, Metalonis SW, Wang X, Roque L, Masters B, Kenyon NS, Ginzburg E, Xu X, Tan J, Caplan AI, Glassberg MK, Alejandro R, Ricordi C. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 2021;10:660-673.
38. Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, Shi L, Wu M, Deng K, Wei J, Wang X, Cao Y, Yan J, Feng G. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 2020;11:361.

APA	CANBAZ H, Idiz U, cankar dal h, Kaciroglu f, Taş S, Çubukçu H, bestemir a, Gülşen M, Polat İ, LALOĞLU A, Tor I, akkurt e, ates u, reisli i, KOÇ E, Inkaya A, Karakukcu M, Ceylan M, Haznedaroglu I, AKIN H (2022). Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. , 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
Chicago	CANBAZ Hayri,Idiz Ufuk Oguz,cankar dal hayriye,Kaciroglu fatih,Taş Seher,Çubukçu Hikmet Can,bestemir attila,Gülşen Murat,Polat İstemi Taha,LALOĞLU Abubekir,Tor Ibrahim Hakki,akkurt ekrem,ates utku,reisli ismail,KOÇ Esin,Inkaya Ahmet Cagkan,Karakukcu Musa,Ceylan Mustafa,Haznedaroglu Ibrahim C.,AKIN HALUK Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. (2022): 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
MLA	CANBAZ Hayri,Idiz Ufuk Oguz,cankar dal hayriye,Kaciroglu fatih,Taş Seher,Çubukçu Hikmet Can,bestemir attila,Gülşen Murat,Polat İstemi Taha,LALOĞLU Abubekir,Tor Ibrahim Hakki,akkurt ekrem,ates utku,reisli ismail,KOÇ Esin,Inkaya Ahmet Cagkan,Karakukcu Musa,Ceylan Mustafa,Haznedaroglu Ibrahim C.,AKIN HALUK Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. , 2022, ss.222 - 229. 10.4274/tjh.galenos.2022.2022.0103
AMA	CANBAZ H,Idiz U,cankar dal h,Kaciroglu f,Taş S,Çubukçu H,bestemir a,Gülşen M,Polat İ,LALOĞLU A,Tor I,akkurt e,ates u,reisli i,KOÇ E,Inkaya A,Karakukcu M,Ceylan M,Haznedaroglu I,AKIN H Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. . 2022; 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
Vancouver	CANBAZ H,Idiz U,cankar dal h,Kaciroglu f,Taş S,Çubukçu H,bestemir a,Gülşen M,Polat İ,LALOĞLU A,Tor I,akkurt e,ates u,reisli i,KOÇ E,Inkaya A,Karakukcu M,Ceylan M,Haznedaroglu I,AKIN H Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. . 2022; 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
IEEE	CANBAZ H,Idiz U,cankar dal h,Kaciroglu f,Taş S,Çubukçu H,bestemir a,Gülşen M,Polat İ,LALOĞLU A,Tor I,akkurt e,ates u,reisli i,KOÇ E,Inkaya A,Karakukcu M,Ceylan M,Haznedaroglu I,AKIN H "Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study." , ss.222 - 229, 2022. 10.4274/tjh.galenos.2022.2022.0103
ISNAD	CANBAZ, Hayri vd. "Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study". (2022), 222-229. https://doi.org/10.4274/tjh.galenos.2022.2022.0103

APA	CANBAZ H, Idiz U, cankar dal h, Kaciroglu f, Taş S, Çubukçu H, bestemir a, Gülşen M, Polat İ, LALOĞLU A, Tor I, akkurt e, ates u, reisli i, KOÇ E, Inkaya A, Karakukcu M, Ceylan M, Haznedaroglu I, AKIN H (2022). Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. Turkish Journal of Hematology, 39(4), 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
Chicago	CANBAZ Hayri,Idiz Ufuk Oguz,cankar dal hayriye,Kaciroglu fatih,Taş Seher,Çubukçu Hikmet Can,bestemir attila,Gülşen Murat,Polat İstemi Taha,LALOĞLU Abubekir,Tor Ibrahim Hakki,akkurt ekrem,ates utku,reisli ismail,KOÇ Esin,Inkaya Ahmet Cagkan,Karakukcu Musa,Ceylan Mustafa,Haznedaroglu Ibrahim C.,AKIN HALUK Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. Turkish Journal of Hematology 39, no.4 (2022): 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
MLA	CANBAZ Hayri,Idiz Ufuk Oguz,cankar dal hayriye,Kaciroglu fatih,Taş Seher,Çubukçu Hikmet Can,bestemir attila,Gülşen Murat,Polat İstemi Taha,LALOĞLU Abubekir,Tor Ibrahim Hakki,akkurt ekrem,ates utku,reisli ismail,KOÇ Esin,Inkaya Ahmet Cagkan,Karakukcu Musa,Ceylan Mustafa,Haznedaroglu Ibrahim C.,AKIN HALUK Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. Turkish Journal of Hematology, vol.39, no.4, 2022, ss.222 - 229. 10.4274/tjh.galenos.2022.2022.0103
AMA	CANBAZ H,Idiz U,cankar dal h,Kaciroglu f,Taş S,Çubukçu H,bestemir a,Gülşen M,Polat İ,LALOĞLU A,Tor I,akkurt e,ates u,reisli i,KOÇ E,Inkaya A,Karakukcu M,Ceylan M,Haznedaroglu I,AKIN H Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. Turkish Journal of Hematology. 2022; 39(4): 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
Vancouver	CANBAZ H,Idiz U,cankar dal h,Kaciroglu f,Taş S,Çubukçu H,bestemir a,Gülşen M,Polat İ,LALOĞLU A,Tor I,akkurt e,ates u,reisli i,KOÇ E,Inkaya A,Karakukcu M,Ceylan M,Haznedaroglu I,AKIN H Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study. Turkish Journal of Hematology. 2022; 39(4): 222 - 229. 10.4274/tjh.galenos.2022.2022.0103
IEEE	CANBAZ H,Idiz U,cankar dal h,Kaciroglu f,Taş S,Çubukçu H,bestemir a,Gülşen M,Polat İ,LALOĞLU A,Tor I,akkurt e,ates u,reisli i,KOÇ E,Inkaya A,Karakukcu M,Ceylan M,Haznedaroglu I,AKIN H "Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study." Turkish Journal of Hematology, 39, ss.222 - 229, 2022. 10.4274/tjh.galenos.2022.2022.0103
ISNAD	CANBAZ, Hayri vd. "Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study". Turkish Journal of Hematology 39/4 (2022), 222-229. https://doi.org/10.4274/tjh.galenos.2022.2022.0103